The therapeutic potential of PARPi’s has been tested in an explant of primary human tumors, showing that inhibition of the PARP1 enzyme leads to a decrease in tumor proliferation, all the more so when simultaneous inhibition of DSB repair via maximal androgen deprivation is achieved (28). The gene discussed is PARP1; the disease is neoplasm.